Related references
Note: Only part of the references are listed.CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients
Vivian Iida Avelino-Silva et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Increased Tryptophan Catabolism Is Associated With Increased Frequency of CD161+Tc17/MAIT Cells and Lower CD4+T-Cell Count in HIV-1 Infected Patients on cART After 2 Years of Follow-Up
Julie C. Gaardbo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
Jens D. Lundgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
Christine Danel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Serious adverse events associated with yellow fever vaccine
Reinaldo de Menezes Martins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Influence of the Timing of Antiretroviral Therapy on the Potential for Normalization of Immune Status in Human Immunodeficiency Virus 1-Infected Individuals
Jason F. Okulicz et al.
JAMA INTERNAL MEDICINE (2015)
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study
Cristina Mussini et al.
LANCET HIV (2015)
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine
Enoch Muyanja et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy
Helen Byakwaga et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment
Allan R. Tenorio et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection
Peter W. Hunt et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality
Sergio Serrano-Villar et al.
PLOS PATHOGENS (2014)
CD4+ T-cell activation impairs serogroup C Neisseria meningitis vaccine response in HIV-infected children
Lucimar G. Milagres et al.
AIDS (2013)
GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals
Jack T. Stapleton et al.
AIDS (2013)
Yellow fever vaccine viremia following ablative BM suppression in AML
V. I. Avelino-Silva et al.
BONE MARROW TRANSPLANTATION (2013)
Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size
Vivek Jain et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Impaired Antibody Response to Influenza Vaccine in HIV-Infected and Uninfected Aging Women Is Associated with Immune Activation and Inflammation
Anita Parmigiani et al.
PLOS ONE (2013)
A simple LC-MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients
Yong Huang et al.
BIOANALYSIS (2013)
Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies
Marisol Simoes et al.
BIOLOGICALS (2012)
Plasma HIV-RNA Is the Key Determinant of Long-Term Antibody Persistence After Yellow Fever Immunization in a Cohort of 364 HIV-Infected Patients
Jerome Pacanowski et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
GB Virus C Viremia Is Associated With Higher Levels of Double-Negative T Cells and Lower T-Cell Activation in HIV-Infected Individuals Receiving Antiretroviral Therapy
Nirjal Bhattarai et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali
Mariam Sidibe et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2012)
HIV and Inflammation: Mechanisms and Consequences
Peter W. Hunt
CURRENT HIV/AIDS REPORTS (2012)
Reduced immunogenicity of influenza vaccines in HIV-infected compared with uninfected pregnant women is associated with regulatory T cells
Kelly Richardson et al.
AIDS (2011)
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy
Peter W. Hunt et al.
AIDS (2011)
Immunogenicity and Tolerability of Yellow Fever Vaccination in 23 French HIV-Infected Patients
Thierry Pistone et al.
CURRENT HIV RESEARCH (2010)
GB virus type C infection modulates T-cell activation independently of HIV-1 viral load
Maria Teresa Maidana-Giret et al.
AIDS (2009)
Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV-Infected Patients
Olivia Veit et al.
CLINICAL INFECTIOUS DISEASES (2009)
Changes in the risk of death after HIV seroconversion compared with mortality in the general population
Krishnan Bhaskaran et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines
N. Mantel et al.
JOURNAL OF VIROLOGICAL METHODS (2008)
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
LANCET (2008)
Adverse event reports following yellow fever vaccination
Nicole P. Lindsey et al.
VACCINE (2008)
Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy
A Weinberg et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Share Paper
